X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1266) 1266
Publication (62) 62
Book Review (8) 8
Newsletter (4) 4
Conference Proceeding (1) 1
Data Set (1) 1
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (756) 756
amifostine (666) 666
amifostine - therapeutic use (664) 664
animals (540) 540
oncology (513) 513
male (479) 479
female (453) 453
radiation-protective agents - therapeutic use (418) 418
mice (290) 290
index medicus (283) 283
radiotherapy (274) 274
middle aged (267) 267
wr-2721 (253) 253
chemotherapy (222) 222
amifostine - administration & dosage (217) 217
aged (216) 216
amifostine - pharmacology (216) 216
adult (215) 215
cancer (189) 189
radiology, nuclear medicine & medical imaging (174) 174
toxicity (163) 163
rats (158) 158
radiation (153) 153
radiation-protective agents - pharmacology (151) 151
irradiation (144) 144
combined modality therapy (143) 143
radiation injuries - prevention & control (143) 143
antineoplastic combined chemotherapy protocols - therapeutic use (142) 142
cisplatin (141) 141
radioprotection (137) 137
antineoplastic agents - adverse effects (134) 134
radiation-protective agents - administration & dosage (127) 127
pharmacology & pharmacy (125) 125
treatment outcome (124) 124
cytoprotection (121) 121
protection (118) 118
therapy (117) 117
amifostine - adverse effects (111) 111
head and neck neoplasms - radiotherapy (107) 107
organothiophosphorus compounds - therapeutic use (104) 104
radiation injuries, experimental - prevention & control (104) 104
neoplasms - drug therapy (100) 100
trial (100) 100
neck-cancer (99) 99
radiotherapy - adverse effects (97) 97
radiation-therapy (92) 92
dose-response relationship, drug (90) 90
time factors (90) 90
antineoplastic agents - therapeutic use (83) 83
head (83) 83
radiotherapy dosage (81) 81
apoptosis (78) 78
antineoplastic combined chemotherapy protocols - adverse effects (77) 77
cells (77) 77
neoplasms - radiotherapy (74) 74
cell lung-cancer (73) 73
cisplatin - adverse effects (73) 73
normal-tissues (71) 71
clinical trials as topic (70) 70
dose-response relationship, radiation (70) 70
drug therapy, combination (69) 69
care and treatment (68) 68
hematology (68) 68
analysis (66) 66
cisplatin - administration & dosage (65) 65
cyclophosphamide (64) 64
rodents (64) 64
xerostomia - etiology (63) 63
health aspects (60) 60
carcinoma (59) 59
lung neoplasms - drug therapy (58) 58
drug administration schedule (57) 57
radiation dosage (57) 57
aged, 80 and over (56) 56
xerostomia - prevention & control (56) 56
adolescent (55) 55
carboplatin (54) 54
medicine & public health (54) 54
prevention (54) 54
radiation-protective agents - adverse effects (54) 54
radiation therapy (53) 53
xerostomia (53) 53
head and neck neoplasms - drug therapy (52) 52
research (52) 52
bone-marrow (51) 51
oxidative stress (51) 51
antioxidants (49) 49
child (49) 49
randomized-trial (49) 49
medicine (48) 48
phase-ii (48) 48
carcinoma, non-small-cell lung - drug therapy (47) 47
carcinoma, squamous cell - radiotherapy (46) 46
colony-stimulating factor (46) 46
lung neoplasms - radiotherapy (46) 46
tumors (46) 46
cell survival - drug effects (45) 45
drugs (45) 45
gamma rays (45) 45
ionizing radiation (44) 44
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1189) 1189
Russian (23) 23
Chinese (15) 15
German (13) 13
French (10) 10
Japanese (6) 6
Polish (5) 5
Czech (2) 2
Serbian (2) 2
Ukrainian (2) 2
Finnish (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 2014, Volume 120, Issue 10, pp. 1453 - 1461
BACKGROUND Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the... 
gastrointestinal | mucositis | guidelines | oral | stomatitis | Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) | HEAD | GASTROINTESTINAL MUCOSITIS | ISOO | CELL TRANSPLANTATION | RANDOMIZED-TRIAL | ZINC SUPPLEMENTATION | NECK-CANCER | ONCOLOGY | MUCOSAL INJURY | ORAL MUCOSITIS | DOUBLE-BLIND | LEVEL LASER THERAPY | Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC | Sucralfate - administration & dosage | Humans | Radiotherapy - adverse effects | Antineoplastic Agents - administration & dosage | Protective Agents - therapeutic use | Mucositis - prevention & control | Proctitis - prevention & control | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Neoplasms - radiotherapy | Intercellular Signaling Peptides and Proteins - administration & dosage | Low-Level Light Therapy | Esophagitis - therapy | Analgesics - therapeutic use | Proctitis - therapy | Anti-Infective Agents - therapeutic use | Evidence-Based Medicine | Mucositis - therapy | Cytokines - administration & dosage | Esophagitis - etiology | Stomatitis - etiology | Mucositis - chemically induced | Oral Hygiene | Anti-Ulcer Agents - administration & dosage | Neoplasms - drug therapy | Phototherapy | Stomatitis - therapy | Proctitis - etiology | Mucositis - etiology | Stomatitis - chemically induced | Esophagitis - prevention & control | Radiation-Protective Agents - therapeutic use | Stomatitis - prevention & control | Amifostine - therapeutic use | Cryotherapy | Hyperbaric Oxygenation | Practice guidelines (Medicine) | Usage | Care and treatment | Mucositis | Analysis | Cancer | Index Medicus | Abridged Index Medicus | Review
Journal Article
Journal Article
Journal Article
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2015, Volume 93, Issue 4, pp. 892 - 900
Purpose To test the effects of a novel Mn porphyrin oxidative stress modifier, Mn(III) meso- tetrakis( N -n-butoxyethylpyridinium-2-yl)porphyrin (MnBuOE), for... 
Radiology | Hematology, Oncology and Palliative Medicine | IRRADIATION | ONCOLOGY | AMIFOSTINE | RADIOPROTECTOR | PAROTID-GLAND | MACROPHAGES | INTENSITY-MODULATED RADIOTHERAPY | DYSFUNCTION | RADIATION | POLARIZATION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | MNTE-2-PYP5 | Organs at Risk - radiation effects | Salivary Glands - pathology | Radiation-Protective Agents - pharmacokinetics | Radiation-Sensitizing Agents - pharmacokinetics | Organs at Risk - pathology | Radiation-Sensitizing Agents - therapeutic use | Mouth Mucosa - radiation effects | Metalloporphyrins - therapeutic use | Radiation Injuries, Experimental - prevention & control | Salivary Glands - radiation effects | Fibrosis - prevention & control | Metalloporphyrins - pharmacokinetics | Drug Evaluation, Preclinical - methods | Mice, Inbred C57BL | Radiation Dosage | Random Allocation | Stomatitis - etiology | Xerostomia - prevention & control | Head and Neck Neoplasms - radiotherapy | Animals | Mice, Nude | Fibrosis - etiology | Radiation-Protective Agents - therapeutic use | Stomatitis - prevention & control | Mice | Xerostomia - etiology | Dose-Response Relationship, Radiation | Sects | Superoxide | Health aspects | Cancer | Biomedical engineering | Porphyrins | NEOPLASMS | BIOMEDICAL RADIOGRAPHY | SALIVARY GLANDS | RADIOLOGY AND NUCLEAR MEDICINE | PLANT TISSUES | ANIMAL TISSUES | RADIATION DOSES | RADIOTHERAPY | RADIATION INJURIES | MUCOUS MEMBRANES
Journal Article
Cancer, ISSN 0008-543X, 07/2011, Volume 117, Issue 13, pp. 3004 - 3013
Journal Article